Preclinical: Targeting NSD2, a Promising Strategy Against Treatment-Induced Neuroendocrine Prostate Cancer
/0 Comments/in Preclinical Research/by MaxASCO GU 2025: Gut-Driven Breakthrough, New Study Links Prostate Cancer Slowing to Phytochemicals and Probiotics
/0 Comments/in Clinical Trial, Localized/by MaxASCO GU 2025: Darolutamide Triplet Therapy Outperforms Alternatives in Advanced Prostate Cancer
/0 Comments/in Retrospective studies/by MaxAI Strikes Again: FDA Cleared an AI That Outperformed Human Pathologists in Missed Cases
/0 Comments/in Artificial Intelligence/by MaxUpdate Phase 1: Mevrometostat Shows Promise in Prostate Cancer by Targeting EZH2
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxThe Microbiome: A Frontline Barrier and Emerging Ally in Cancer Treatment
/0 Comments/in Clinical Trial, Not PCa related/by MaxBR111: A New ADC Therapy That Could Work Also For Prostate Cancer
/0 Comments/in Clinical Trial, Not PCa related/by MaxHyperthermia: Where Are We With Solid Tumors?
/0 Comments/in Hyperthermia, Preclinical Research/by MaxNewsletter 6/2025
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi, fellow fighters! This week, the updates are primarily in clinical research, we could call it the Nectin-4 week! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. Since I’ll need to […]
Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy castration-resistant prostate cancer CDK12 clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology olaparib oncolytic virus personalized medicine prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 23/2025 June 8, 2025
- Protein Design Leaps Forward Thanks to AI June 5, 2025
- Phase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors June 5, 2025
- UPDATE About ACE-232: Phase 1 Trial of a Novel CYP11A1 Inhibitor for mCRPC June 5, 2025